Associated Papers
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
36561320 (PubMed )
Supplement: Table3.xlsx › Sheet1
Pancreatic Cancer-Related Mutational Burden Is Not Increased in a Patient Cohort With Clinically Severe Chronic Pancreatitis.
Cowan RW et al.
Clinical and Translational Gastroenterology, 2021
34797250 (PubMed )
Supplement: ct9-12-e00431-s005.xlsx › SDC5
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area.
Hsieh CH et al.
Head & Neck, 2011
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.
Foster JM et al.
World Journal of Surgical Oncology, 2010
EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan.
Huang SF et al.
Head & Neck, 2009
Select a paper to view details